Erratum: Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment

Attner P, Näsman A, Du J, Hammarstedt L, Ramqvist T, Lindholm J, Munck-Wikland E, Dalianis T, Marklund L. Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer. 2012 Sep 1;131(5):1124–30. doi: 10.1002/ijc.26490. Epub 2011 Nov 28.

After publication, it was noted that the information regarding one of the treatment groups was incomplete. The sentence starting on page 1125, 3rd paragraph should read:

Treatment was categorized as (i) conventional radiotherapy (2.0 Gy/day, for 6.5–7 weeks, total dose: 68 Gy) or (ii) accelerated radiotherapy (1.1 + 2.0 Gy/day for 4.5 weeks, total dose: 68 Gy) or (iii) chemotherapy consisting of Cisplatin 75–100 mg/kvm and 5-fluorouracil 1000 mg/kvm/24 h (administered during 4–5 days) with or without docetaxel [(Taxotere^®) 75 mg/kvm], followed by either conventional or accelerated radiotherapy, and here 4 patients received concomitant therapy with Cetuximab.

We apologize for the oversight and inconvenience.

DOI: 10.1002/ijc.27722